4 completed, 2 terminated, 1 recruiting, 1 unknown. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Terminated 2, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Familial Hypercholesterolemia: new trials by email Literature Review of Familial Hypercholesterolemia trials Research Report on Familial Hypercholesterolemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH) 2-Hydroxybenzylamine, Placebo - Familial Hypercholesterolemia | Phase 2 | Recruiting | Vanderbilt University Medical Center | 72 | 2024-02-14 | 2026-08-07 |
| A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008) Enclitide Chloride, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 381 | 2022-03-10 | 2024-12-09 |
| A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia SHR-1209 - Familial Hypercholesterolemia | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 8 | 2020-09-01 | 2020-07-02 |
| An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol Inclisiran, Evolocumab - Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis | Phase 2 | Completed | Novartis Pharmaceuticals | 382 | 2017-04-27 | 2023-03-24 |
| Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) ALN-PCSSC, Normal Saline - Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia | Phase 2 | Completed | The Medicines Company | 501 | 2016-01-01 | 2019-05-17 |
| Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia Lactobacillus paracasei B21060, low satured diet - Dyslipidemia, Familial Hypercholesterolemia | Phase 1 / Phase 2 | Completed | Federico II University | 40 | 2012-01-01 | 2014-01-29 |
| Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients APL180, Placebo - Familial Hypercholesterolemia | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2006-09-01 | 2016-09-23 | |
| Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy Implitapide - Familial Hypercholesterolemia | Phase 2 | Terminated | Medical Research Laboratories International | 120 | 2003-10-01 | 2005-06-24 |
| Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy Implitapide - Familial Hypercholesterolemia | Phase 2 | Terminated | Medical Research Laboratories International | 60 | 2003-09-01 | 2005-06-24 |
Hyperlipoproteinemia Type II (9) · Atherosclerosis (2) · Diabetes Mellitus (1) · Dyslipidemias (1) · Homozygous Familial Hypercholesterolemia (1) · Hypercholesterolemia (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Hyperlipidemias (9) · Hyperlipoproteinemias (9) · Lipid Metabolism Disorders (9) · Lipid Metabolism, Inborn Errors (9) · Metabolic Diseases (9) · Metabolism, Inborn Errors (9) · Nutritional and Metabolic Diseases (9) · Dyslipidemias (8) · Arterial Occlusive Diseases (2) · Arteriosclerosis (2) · Cardiovascular Diseases (2) · Vascular Diseases (2) · Endocrine System Diseases (1)
ALN-PCS (2) · implitapide (2) · 2-(aminomethyl)phenol (1) · MK-0616 (1) · Saline Solution (1) · evolocumab (1)
Medical Research Laboratories International (2) · Novartis Pharmaceuticals (2) · Federico II University (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Merck Sharp & Dohme LLC (1) · The Medicines Company (1) · Vanderbilt University Medical Center (1)
United States (6) · Netherlands (4) · Canada (3) · Germany (3) · Norway (3) · United Kingdom (3) · Israel (1) · Japan (1) · Mexico (1) · South Korea (1) · Turkey (Türkiye) (1)
Kausik K Ray, MD (1) · Kausik Ray, MD (1) · MacRae F. Linton, MD (1)
PMID 28306389, PMID 29735484, PMID 30487231, PMID 31553410, PMID 31630870, PMID 33990512, PMID 36620965, PMID 36889610, PMID 38063346, PMID 40587053
2016 (1), P01HL116263 (1)